Guru P. Sonpavde, MD, is the director of Genitourinary Oncology and Phase I Research as well as the Christopher K. Glanz Chair for Bladder Cancer Research at the AdventHealth Cancer Institute, and professor of medicine at the University of Central Florida, Orlando, Florida. Previously, he was the Bladder Cancer director at the Dana-Farber Cancer Institute and associate professor of medicine at Harvard Medical School from 2017–2022, GU Oncology director and associate professor of medicine at the University of Alabama at Birmingham from 2012–2017, and practiced from 2004–2012 at Texas Oncology, a US Oncology affiliate. His focus is drug development (including early development Phase 1 clinical trials and later Phase 2/3 trials) evaluating novel and emerging classes of treatments across solid tumors and clinical/translational research to cure GU cancers with a focus on bladder cancer.